AcousticaBio
Private Company
Funding information not available
Overview
AcousticaBio is a venture-backed, NIH-funded biotech startup, spun out from Harvard in 2022, focused on revolutionizing biologic drug delivery. The company's core innovation is a gentle, acoustophoretic fluid processing technology that creates stable, ultra-high concentration (>500 mg/mL) microgel suspensions of monoclonal antibodies, enabling small-volume subcutaneous dosing. By transforming IV-infused drugs into simple injections, AcousticaBio seeks to improve patient access and adherence, reduce healthcare costs, and create significant value for biopharmaceutical partners through collaborative formulation development.
Technology Platform
Proprietary acoustophoretic fluid processing technology that formulates monoclonal antibodies and other biologics into ultra-high concentration (>500 mg/mL), low-viscosity microgel suspensions for subcutaneous injection.
Opportunities
Risk Factors
Competitive Landscape
AcousticaBio competes with other drug delivery companies developing high-concentration subcutaneous technologies, such as those using novel excipients, co-formulations, or delivery devices. It also competes with large biopharma internal formulation teams and established CDMOs offering formulation services.